Non-suppression of testosterone in patients with a rising prostate-specific antigen level receiving luteinising hormone-releasing hormone analogues for metastatic prostate cancer.
Koupparis
A J
AJ
Tyrrell
C
C
D000970:Antineoplastic Agents / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000096:biosynthesis / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013739:Testosterone / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017430:Prostate-Specific Antigen